Biofrontera restructures relationship with Biofrontera AG, backed by $11M investment

1 week ago 1

Biofrontera (NASDAQ:BFRI) said on Monday that it has acquired all U.S. Rights to Ameluz and RhodoLED from its former parent company Biofrontera AG.

An $11M investment led by Rosalind Advisors and AIGH Capital Management funded the acquisition and transfer costs.

Biofrontera

Recommended For You

More Trending News

Read Entire Article